$2.5M Gene Therapy Gives Sisters a Future

Nine-month-old Willow McIntosh wobbles forward, gripping her dad's fingers as she learns to walk. For most families, these first steps are precious but ordinary. For the McIntosh family in Brisbane, Australia, they're nothing short of miraculous.

Willow was born with spinal muscular atrophy type 1, a genetic disorder that once meant certain death before age two. Without treatment, the condition destroys motor neurons in the spinal cord, leading to progressive muscle weakness and respiratory failure.

Her older sister Reena, now seven, was diagnosed with the same condition in 2019 at five months old. Back then, her parents Katie and Clayton faced a heartbreaking reality. They went home wondering if they should celebrate her half birthday, unsure if she'd survive to see a full year.

But Reena arrived at a turning point in medical history. Just months earlier, the first effective treatment called Spinraza had become available. The drug works by increasing a vital protein that keeps motor neurons alive. Once these nerve cells die, they can't be brought back, so early treatment is everything.

Reena received her first injection the day after diagnosis. At 16 months, the Australian government granted her special access to Zolgensma, a one-time gene therapy that costs about $2.5 million per dose. The treatment hadn't even been officially approved yet, but it worked.

Today, Reena uses a wheelchair and receives ongoing therapy through Australia's disability support system. She's in second grade and loves being a big sister. Her parents try not to take any of it for granted.

When Katie became pregnant with Willow, the family had something Reena never had: early detection. Since November 2023, Australia has publicly funded genetic screening for spinal muscular atrophy and other conditions during pregnancy. Willow was diagnosed while still in the womb.

That early warning made all the difference. Willow received treatment immediately after birth, before any motor neurons were lost. The results speak for themselves in those wobbly first steps.

About one in 10,000 babies is born with spinal muscular atrophy. One in 50 people carries the gene mutation without knowing it. Early screening and rapid treatment are now giving families hope where there was none before.

Why This Inspires

A decade ago, families facing a spinal muscular atrophy diagnosis had no good options. Today, children like Reena and Willow are growing up, going to school, and hitting milestones that seemed impossible. Their story reminds us that medical breakthroughs aren't just statistics in journals. They're little girls learning to walk, big sisters painting family portraits, and parents who get to plan for birthdays instead of funerals. Science is rewriting what's possible, one family at a time.

The McIntosh family now looks toward futures they once couldn't imagine.